表紙
市場調査レポート

Trillium Therapeutics Inc. : 製品パイプライン分析

Trillium Therapeutics Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 251728
出版日 ページ情報 英文 21 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
Trillium Therapeutics Inc. : 製品パイプライン分析 Trillium Therapeutics Inc. - Product Pipeline Review - 2015
出版日: 2015年08月12日 ページ情報: 英文 21 Pages
概要

Trillium Therapeutics Inc.は、免疫介在疾患の治療薬を発見し、開発しているバイオ製薬会社で、特に細胞保護作用と免疫調節の二つの分野に力を入れています。また、膀胱炎と癌の治療薬開発にも取り組んでいます。

当レポートでは、Trillium Therapeutics Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Trillium Therapeutics Inc.の基本情報

Trillium Therapeutics Inc.の概要

  • 主要情報
  • 企業情報

Trillium Therapeutics Inc.:R&Dの概要

  • 主な治療範囲

Trillium Therapeutics Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Trillium Therapeutics Inc.:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

Trillium Therapeutics Inc.:薬剤プロファイル

  • tigecycline
  • TTI-1612
  • CD200-Specific Monoclonal Antibody
  • TTI-621
  • TTI-622

Trillium Therapeutics Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Trillium Therapeutics Inc.:最近のパイプライン動向

Trillium Therapeutics Inc.:休止中のプロジェクト

Trillium Therapeutics Inc.:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • (human chorionic gonadotropin-Beta + epoeitin alfa)

Trillium Therapeutics Inc.:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07489CDB

Summary

Global Markets Direct's, 'Trillium Therapeutics Inc. - Product Pipeline Review - 2015', provides an overview of the Trillium Therapeutics Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Trillium Therapeutics Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Trillium Therapeutics Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Trillium Therapeutics Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Trillium Therapeutics Inc.'s pipeline products

Reasons to buy

  • Evaluate Trillium Therapeutics Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Trillium Therapeutics Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Trillium Therapeutics Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Trillium Therapeutics Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Trillium Therapeutics Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Trillium Therapeutics Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Trillium Therapeutics Inc. Snapshot
    • Trillium Therapeutics Inc. Overview
    • Key Information
    • Key Facts
  • Trillium Therapeutics Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Trillium Therapeutics Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Trillium Therapeutics Inc. - Pipeline Products Glance
    • Trillium Therapeutics Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Trillium Therapeutics Inc. - Drug Profiles
    • Monoclonal Antibody to Inhibit CD200 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TTI-508
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TTI-621
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TTI-622
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Trillium Therapeutics Inc. - Pipeline Analysis
    • Trillium Therapeutics Inc. - Pipeline Products by Target
    • Trillium Therapeutics Inc. - Pipeline Products by Molecule Type
    • Trillium Therapeutics Inc. - Pipeline Products by Mechanism of Action
  • Trillium Therapeutics Inc. - Recent Pipeline Updates
  • Trillium Therapeutics Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Trillium Therapeutics Inc., Key Information
  • Trillium Therapeutics Inc., Key Facts
  • Trillium Therapeutics Inc. - Pipeline by Indication, 2015
  • Trillium Therapeutics Inc. - Pipeline by Stage of Development, 2015
  • Trillium Therapeutics Inc. - Monotherapy Products in Pipeline, 2015
  • Trillium Therapeutics Inc. - Preclinical, 2015
  • Trillium Therapeutics Inc. - Pipeline by Target, 2015
  • Trillium Therapeutics Inc. - Pipeline by Molecule Type, 2015
  • Trillium Therapeutics Inc. - Pipeline Products by Mechanism of Action, 2015
  • Trillium Therapeutics Inc. - Recent Pipeline Updates, 2015

List of Figures

  • Trillium Therapeutics Inc. - Pipeline by Top 10 Indication, 2015
  • Trillium Therapeutics Inc. - Pipeline by Top 10 Target, 2015
  • Trillium Therapeutics Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Trillium Therapeutics Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top